Table 2.
Clinical settings associated with HLA-C alleles
| Disease | Type of disease | HLA-C alleles | Type of association | References |
|---|---|---|---|---|
| Genital herpes simplex type 2 | Infection | Cw*02 | Severity of infection | Lekstrom-Himes et al., 1999 |
| Cw*04 | Susceptibility | Lekstrom-Himes et al., 1999 | ||
| Nasopharyngeal carcinoma | Cancer | Cw*0401 | Protection | Butsch Kovacic et al., 2005 |
| Human immunodeficiency virus | Infection | Cw*0401 | Protection (with B*8101) | Leslie et al. 2010 |
| B35 Cw4 haplotype | Rapid disease progression | Carrington, 1999 | ||
| Cw*12 | Protection | Thomas et al., 2009 | ||
| HLTV-1 | Infection | Cw*08 | Protection | Jeffery et al., 2000 |
| Cervical neoplasia | Cancer | HLA-C2 | Protection | Carrington et al., 2005 |
| Homozygosity | Invasive disease | Martin et al.35 | ||
| HLA-C1 | ||||
| Hepatitis C virus | Infection | HLA-C1 homozygosity | Protection in presence of KIR2DL3 | Khakoo et al.23 |
| Multinodular goitre | Autoimmunity | Cw*0401 | Protection | Rios et al., 2006 |
| Graves’ disease | Autoimmunity | Cw*03 | Protection | Simmonds et al., 2007 |
| Cw*07 | Susceptibility | Simmonds et al., 2007 | ||
| Cw*16 | Protection | Simmonds et al., 2007 | ||
| Psoriasis vulgaris | Autoimmunity | Cw*0501 | Protection when with HLA-A*3002 and B*1801 | Contu et al., 2004 |
| Cw*06 | Susceptibility | Szczerkowska-Dobosz et al., 2004 | ||
| Type I autoimmune hepatitis | Autoimmunity | Cw*0701 | Susceptibility | Strettell et al., 1997 |
| Psoriatic arthritis | Autoimmunity | Cw*0602 | Susceptibility | Gladman et al., 1999 |
| Cw*12 | Susceptibility | Liao and colleagues43 | ||
| Idiopathic inflammatory myopathies | Autoimmunity | Cw*0702 | Protection | O'Hanlon et al., 2005 |
| Primary sclerosing cholangitis | Autoimmunity | HLA-C1homozygosity | Susceptibility | Hov et al.22 |